The European Medicines Agency (EMA) on Tuesday received an application from AstraZeneca and Oxford University for authorization of their COVID-19 vaccine, it said in a statement.
EMA said the decision could be announced on Jan. 29 at the meeting of its Committee for Medicinal Products for Human Use (CHMP) if the vaccine is proven to be safe and effective.
???? AstraZeneca and Oxford University have applied for authorisation for their coronavirus #vaccine in the EU with a decision possible by January 29, the European Medicines Agency says https://t.co/HSWQCMnS1G For @AFP #oxfordastrazeneca #oxfordvaccine pic.twitter.com/6VaHLgQpgI
— EU Data News Hub?? (@EUDataNewsHub) January 12, 2021
“Such a short timeframe for evaluation is only possible because EMA has already reviewed some data on the vaccine during a rolling review,” the press release said.
EMA has assessed analysis from the UK, Brazil, and South Africa, the countries that approved the vaccine previously, on its safety and efficacy, said the agency, adding that it also reviewed "data from laboratory studies (non-clinical data), data on the vaccine’s quality (on its ingredients and the way it is manufactured).”
The European Medicines Agency has received a request for approval from AstraZeneca for the Covid-19 vaccine it developed with Oxford University.https://t.co/hCclCrq97z
— RTÉ News (@rtenews) January 12, 2021
The EU authorized the use of COVID-19 vaccines from Pfizer-BioNTech on Dec. 21, and Moderna on Jan. 6.
This article has been adapted from its original source.